Standard Operating Procedure: Randomized Controlled Trial (RCT) Execution

This Standard Operating Procedure (SOP) outlines the mandatory operational requirements for conducting a Randomized Controlled Trial (RCT). Adherence to this protocol ensures scientific rigor, regulatory compliance (GCP/ICH standards), and data integrity throughout the trial lifecycle. The objective is to minimize bias, standardize participant management, and maintain the highest ethical standards from protocol approval to final data lock.

1. Study Setup and Regulatory Compliance

• Protocol Finalization: Confirm the study protocol is signed, dated, and approved by the Institutional Review Board (IRB) or Ethics Committee (EC).
• Regulatory Filings: Ensure all clinical trial registration (e.g., ClinicalTrials.gov) is completed and public-facing entries are updated.
• Site Initiation: Complete site-specific training for all sub-investigators and clinical research coordinators (CRCs).
• Documentation: Verify that the Investigator Site File (ISF) is populated with CVs, financial disclosures, and delegation of authority logs.

2. Participant Recruitment and Informed Consent

• Screening Logs: Maintain a comprehensive log of all potential candidates, ensuring reasons for screen failure are documented for bias analysis.
• Informed Consent Process: Verify that the current, IRB-approved Informed Consent Form (ICF) is utilized and that the participant has signed prior to any study-related procedures.
• Eligibility Verification: Confirm that all inclusion/exclusion criteria are met; attach supporting medical records or lab results to the electronic Case Report Form (eCRF).

3. Randomization and Blinding Procedures

• Randomization Execution: Utilize a validated Interactive Response Technology (IRT/IWRS) system to ensure concealed allocation.
• Blinding Integrity: Confirm that site staff, participants, and outcomes assessors remain blinded as per protocol; establish an emergency unblinding procedure (e.g., sealed envelopes or 24/7 hotline).
• Drug Accountability: Log the receipt, storage, dispensing, and return of investigational products to ensure no leakage of unblinded information.

4. Intervention and Data Collection

• Visit Compliance: Execute the visit schedule within the allowable time windows defined in the protocol.
• Outcome Measurement: Ensure standardized instruments (e.g., patient-reported outcome measures, calibrated medical devices) are used consistently across all study sites.
• Adverse Event (AE) Monitoring: Perform active surveillance for AEs and ensure timely reporting to the safety monitoring board and regulatory bodies.

5. Quality Control and Data Management

• Source Data Verification (SDV): Compare 100% of eCRF entries against the source medical records to ensure accuracy.
• Query Resolution: Address data queries issued by monitors or data management teams within 48–72 hours.
• Audit Trail: Maintain an electronic audit trail for all data modifications, including user identity and timestamp.

Pro Tips & Pitfalls

• Pro Tip (The Power of Pilots): Always conduct a "dry run" with a single participant to test the randomization system and data capture flow before full-scale recruitment.
• Pro Tip (Standardization): If using subjective measurements (e.g., physical exam scores), hold an inter-rater reliability session for all investigators to ensure consistency in scoring.
• Pitfall (Protocol Deviation): Avoid "protocol drift" by holding bi-weekly site meetings to address recurring questions or minor deviations before they become systematic errors.
• Pitfall (Retention): Neglecting participant engagement strategies is a leading cause of RCT failure; ensure a dedicated budget for participant communication and retention efforts.

Frequently Asked Questions (FAQ)

Q: What is the most common reason for an RCT to be disqualified during an audit? A: Failure to maintain a clear, consistent, and time-stamped audit trail for data entries, or performing study procedures prior to obtaining documented informed consent.

Q: How do we handle a protocol deviation that occurs due to an emergency? A: Prioritize participant safety immediately. Once the emergency is resolved, document the deviation in the source record, notify the PI, and report the event to the IRB/EC within the window specified by your institutional policy.

Q: Can I unblind a participant if they require medical treatment for a non-related condition? A: Only if the treatment requires knowledge of the investigational product to prevent harm. Always attempt to contact the medical monitor or PI before unblinding to confirm that no other course of action is viable.